{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:44:42Z","timestamp":1789382682613,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for sex, prognostic score, and treatment. History of any of the eight autoimmune conditions ranged from 7.4% in HL to 18.2% in MZL, and was not associated with EFS or OS for any lymphoma subtype. However, there was a positive association of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR\u2009=\u20092.23, CI: 1.15\u20134.34) and HL (HR\u2009=\u20092.63, CI: 1.04\u20136.63), which was largely driven by rheumatoid arthritis. Autoimmune conditions primarily mediated by T-cell responses were not found to be associated with EFS or OS in any lymphoma subtype, although there were few events for this exposure. Our results indicate that distinguishing autoimmune conditions primarily mediated by B-cell\/T-cell responses may yield insight regarding the impact of this comorbid disease, affecting ~10% of lymphoma patients, on survival.<\/jats:p>","DOI":"10.1038\/s41408-018-0105-4","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T12:31:26Z","timestamp":1533126686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["History of autoimmune conditions and lymphoma prognosis"],"prefix":"10.1038","volume":"8","author":[{"given":"Geffen","family":"Kleinstern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Liebow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Koff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Allmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana N.","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-4808","authenticated-orcid":false,"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"105_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893\u20132917 (2010).","journal-title":"Int. J. Cancer"},{"key":"105_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2559.2010.03696.x","volume":"58","author":"E Roman","year":"2011","unstructured":"Roman, E. & Smith, A. G. Epidemiology of lymphomas. Histopathology 58, 4\u201314 (2011).","journal-title":"Histopathology"},{"key":"105_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3816\/CLM.2009.n.042","volume":"9","author":"H Mani","year":"2009","unstructured":"Mani, H. & Jaffe, E. S. Hodgkin lymphoma: an update on its biology with new insights into classification. Clin. Lymphoma Myeloma 9, 206\u2013216 (2009).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"105_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","volume":"2","author":"GS Cooper","year":"2003","unstructured":"Cooper, G. S. & Stroehla, B. C. The epidemiology of autoimmune diseases. Autoimmun. Rev. 2, 119\u2013125 (2003).","journal-title":"Autoimmun. Rev."},{"key":"105_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9343(85)90242-6","volume":"78","author":"T Hakulinen","year":"1985","unstructured":"Hakulinen, T., Isomaki, H. & Knekt, P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am. J. Med. 78, 29\u201332 (1985).","journal-title":"Am. J. Med."},{"key":"105_CR6","first-page":"201","volume-title":"Cancer Causes Control","author":"M Kauppi","year":"1997","unstructured":"Kauppi, M., Pukkala, E. & Isom\u00e4ki, H. Elevated incidence of hematologic malignancies in patients with Sj\u00f6gren\u2019s syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8, (201\u2013204 (1997)."},{"key":"105_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/art.1780390625","volume":"39","author":"M Abu-Shakra","year":"1996","unstructured":"Abu-Shakra, M., Gladman, D. D. & Urowitz, M. B. Malignancy in systemic lupus erythematosus. Arthritis Rheum. 39, 1050\u20131054 (1996).","journal-title":"Arthritis Rheum."},{"key":"105_CR8","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","volume":"165","author":"E Zintzaras","year":"2005","unstructured":"Zintzaras, E., Voulgarelis, M. & Moutsopoulos, H. M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch. Intern. Med. 165, 2337\u20132344 (2005).","journal-title":"Arch. Intern. Med."},{"key":"105_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/ijc.24287","volume":"125","author":"LA Anderson","year":"2009","unstructured":"Anderson, L. A. et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int. J. Cancer 125, 398\u2013405 (2009).","journal-title":"Int. J. Cancer"},{"key":"105_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jncimonographs\/lgu013","volume":"2014","author":"LM Morton","year":"2014","unstructured":"Morton, L. M. et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J. Natl Cancer Inst. Monogr. 2014, 130\u2013144 (2014).","journal-title":"J. Natl Cancer Inst. Monogr."},{"key":"105_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jncimonographs\/lgu010","volume":"2014","author":"JR Cerhan","year":"2014","unstructured":"Cerhan, J. R. et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J. Natl Cancer Inst. Monogr. 2014, 15\u201325 (2014).","journal-title":"J. Natl Cancer Inst. Monogr."},{"key":"105_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/jncimonographs\/lgu011","volume":"2014","author":"PM Bracci","year":"2014","unstructured":"Bracci, P. M. et al. Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J. Natl Cancer Inst. Monogr. 2014, 52\u201365 (2014).","journal-title":"J. Natl Cancer Inst. Monogr."},{"key":"105_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1046\/j.1365-3083.2001.00950.x","volume":"54","author":"N Porakishvili","year":"2001","unstructured":"Porakishvili, N. et al. Recent progress in the understanding of B-cell functions in autoimmunity. Scand. J. Immunol. 54, 30\u201338 (2001).","journal-title":"Scand. J. Immunol."},{"key":"105_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000094252","volume":"66","author":"S Ballotti","year":"2006","unstructured":"Ballotti, S., Chiarelli, F. & de Martino, M. Autoimmunity: basic mechanisms and implications in endocrine diseases. Horm. Res. Paediatr. 66, 142\u2013152 (2006).","journal-title":"Horm. Res. Paediatr."},{"key":"105_CR15","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.4049\/jimmunol.1202816","volume":"190","author":"RA Sweet","year":"2013","unstructured":"Sweet, R. A., Cullen, J. L. & Ahlomchik, M. J. Rheumatoid factor B cell memory leads to rapid, switched antibody-forming cell responses. J. Immunol. (Baltimore, MD: 1950) 190, 1974\u20131981 (2013).","journal-title":"J. Immunol. (Baltimore, MD: 1950)"},{"key":"105_CR16","first-page":"131","volume":"13","author":"X Zhang","year":"2013","unstructured":"Zhang, X. et al. Follicular helper Tcells: new insights into mechanisms of autoimmune diseases. Ochsner. J. 13, 131\u2013139 (2013).","journal-title":"Ochsner. J."},{"key":"105_CR17","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","volume":"111","author":"K Ekstrom Smedby","year":"2008","unstructured":"Ekstrom Smedby, K. et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111, 4029\u20134038 (2008).","journal-title":"Blood"},{"key":"105_CR18","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1002\/ijc.27944","volume":"132","author":"JF Simard","year":"2013","unstructured":"Simard, J. F. et al. Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes. Int. J. Cancer 132, 2659\u20132666 (2013).","journal-title":"Int. J. Cancer"},{"key":"105_CR19","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1093\/rheumatology\/ker143","volume":"50","author":"J Ji","year":"2011","unstructured":"Ji, J., Liu, X., Sundquist, K. & Sundquist, J. Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer. Rheumatology 50, 1513\u20131518 (2011).","journal-title":"Rheumatology"},{"key":"105_CR20","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO.2005.04.6227","volume":"24","author":"TR Mikuls","year":"2006","unstructured":"Mikuls, T. R. et al. Prospective study of survival outcomes in Non-Hodgkin\u2019s lymphoma patients with rheumatoid arthritis. J. Clin. Oncol. 24, 1597\u20131602 (2006).","journal-title":"J. Clin. Oncol."},{"key":"105_CR21","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1080\/10428194.2017.1379075","volume":"59","author":"V Jachiet","year":"2018","unstructured":"Jachiet, V. et al. Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. Leuk. Lymphoma 59, 1399\u20131405 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"105_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/1756-185X.13231","volume":"21","author":"YH Shih","year":"2018","unstructured":"Shih, Y. -H., Yang, Y., Chang, K. -H., Chen, Y. -H. & Teng, C. -L. J. Clinical features and outcome of lymphoma patients with pre-existing autoimmune diseases. Int. J. Rheum. Dis. 21, 93\u2013101 (2018).","journal-title":"Int. J. Rheum. Dis."},{"key":"105_CR23","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/j.clml.2017.11.009","volume":"18","author":"JL Koff","year":"2018","unstructured":"Koff, J. L. & Flowers, C. R. Characterizing autoimmune disease-associated diffuse large B-cell lymphoma in a SEER\u2013Medicare Cohort. Clin. Lymphoma Myeloma Leuk. 18, e115\u2013e121 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"105_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/hon.2498","volume":"36","author":"G Kleinstern","year":"2018","unstructured":"Kleinstern, G. et al. Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma. Hematol. Oncol. 36, 457\u2013462 (2018).","journal-title":"Hematol. Oncol."},{"key":"105_CR25","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/ije\/dyx119","volume":"46","author":"JR Cerhan","year":"2017","unstructured":"Cerhan, J. R. et al. Cohort profile: the Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. Int. J. Epidemiol. 46, 1753\u20131754i (2017).","journal-title":"Int. J. Epidemiol."},{"key":"105_CR26","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow, S. H. International Agency for Research on Cancer, World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition, (International Agency for Research on Cancer, Lyon, France, 2008).","edition":"4th edition"},{"key":"105_CR27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/aje\/kwu290","volume":"181","author":"SS Wang","year":"2015","unstructured":"Wang, S. S. et al. Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci. Am. J. Epidemiol. 181, 406\u2013421 (2015).","journal-title":"Am. J. Epidemiol."},{"key":"105_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project.","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 329, 987\u2013994 (1993).","journal-title":"N. Engl. J. Med."},{"key":"105_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster, E. et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111, 558\u2013565 (2008).","journal-title":"Blood"},{"key":"105_CR30","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever, D. et al. A prognostic score for advanced Hodgkin\u2019s disease. New Engl. J. Med. 339, 1506\u20131514 (1998).","journal-title":"New Engl. J. Med."},{"key":"105_CR31","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny, P. et al. Follicular lymphoma International Prognostic Index. Blood 104, 1258\u20131265 (2004).","journal-title":"Blood"},{"key":"105_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2017.176511","volume":"103","author":"SI Tracy","year":"2018","unstructured":"Tracy, S. I. et al. Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica 103, 297\u2013303 (2018).","journal-title":"Haematologica"},{"key":"105_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","volume":"24","author":"E Baecklund","year":"2014","unstructured":"Baecklund, E., Smedby, K. E., Sutton, L.-A., Askling, J. & Rosenquist, R. Lymphoma development in patients with autoimmune and inflammatory disorders\u2013what are the driving forces? Semin. Cancer Biol. 24, 61\u201370 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"105_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/17474086.2016.1180972","volume":"9","author":"JL Koff","year":"2016","unstructured":"Koff, J. L. & Flowers, C. R. B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. Expert Rev. Hematol. 9, 553\u2013561 (2016).","journal-title":"Expert Rev. Hematol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0105-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0105-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0105-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:36:27Z","timestamp":1671536187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0105-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["105"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0105-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]},"assertion":[{"value":"29 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"73"}}